ATE327249T1 - Mutiertes env-gen, mutiertes env-glykoprotein und verwendungen - Google Patents

Mutiertes env-gen, mutiertes env-glykoprotein und verwendungen

Info

Publication number: ATE327249T1
Authority: AT; Austria
Prior art keywords: codes; mutation; region; gene; mutated
Prior art date: 2001-09-06

Application number

AT02777408T

Other languages

English (en)

Inventor

Frederic Bedin

Frederic Reynard

Bernard Verrier

Yasemin Ataman-Oenal

Original Assignee

Biomerieux Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-06

Filing date

2002-09-06

Publication date

2006-06-15

2002-09-06 Application filed by Biomerieux Sa filed Critical Biomerieux Sa

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE327249T1 publication Critical patent/ATE327249T1/de

Links

108700004025 env Genes Proteins 0.000 title abstract 5
101150030339 env gene Proteins 0.000 title abstract 5
108090000288 Glycoproteins Proteins 0.000 title abstract 2
102000003886 Glycoproteins Human genes 0.000 title abstract 2
230000035772 mutation Effects 0.000 abstract 10
108020004705 Codon Proteins 0.000 abstract 4
230000013595 glycosylation Effects 0.000 abstract 3
238000006206 glycosylation reaction Methods 0.000 abstract 3
108010078428 env Gene Products Proteins 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
101710121417 Envelope glycoprotein Proteins 0.000 abstract 1
241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
102100034349 Integrase Human genes 0.000 abstract 1
102100034353 Integrase Human genes 0.000 abstract 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
229960001230 asparagine Drugs 0.000 abstract 1
235000009582 asparagine Nutrition 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT02777408T 2001-09-06 2002-09-06 Mutiertes env-gen, mutiertes env-glykoprotein und verwendungen ATE327249T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0111699A FR2829150B1 (fr)	2001-09-06	2001-09-06	Gene env mute codant pour une glypoproteine du vih-1 et applications

Publications (1)

Publication Number	Publication Date
ATE327249T1 true ATE327249T1 (de)	2006-06-15

Family

ID=8867144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02777408T ATE327249T1 (de)	2001-09-06	2002-09-06	Mutiertes env-gen, mutiertes env-glykoprotein und verwendungen

Country Status (8)

Country	Link
US (1)	US20050065320A1 (de)
EP (1)	EP1423418B1 (de)
JP (1)	JP2005508624A (de)
AT (1)	ATE327249T1 (de)
DE (1)	DE60211717T2 (de)
ES (1)	ES2268105T3 (de)
FR (1)	FR2829150B1 (de)
WO (1)	WO2003020755A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120039923A1 (en) *	2004-09-09	2012-02-16	The Henry M. Jackson Foundation	Modified HIV-1 Envelope Proteins
WO2010040136A2 (en) *	2008-10-04	2010-04-08	The Regents Of The University Of California	Selection of hiv vaccine antigens by use of intrapatient sequence variation to identify mutations in the hiv envelope glycoprotein that affect the binding of broadly neutralizing antibodies
CN118515733B (zh) *	2023-02-20	2025-11-18	菲鹏生物股份有限公司	Hiv蛋白及其在检测hiv抗体中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6103238A (en) *	1992-03-13	2000-08-15	President And Fellows Of Harvard College	Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines
AU6535898A (en) *	1997-03-14	1998-10-12	President And Fellows Of Harvard College	Glycosylation deficient siv and hiv envelope glycoproteins
WO1999024465A1 (en) *	1997-11-10	1999-05-20	Dana-Farber Cancer Institute	Stabilized primate lentivirus envelope glycoproteins
US6710173B1 (en) *	1999-06-25	2004-03-23	Progenics Pharmaceuticals, Inc.	Stabilized viral envelope proteins and uses thereof

2001
- 2001-09-06 FR FR0111699A patent/FR2829150B1/fr not_active Expired - Fee Related
2002
- 2002-09-06 DE DE60211717T patent/DE60211717T2/de not_active Expired - Fee Related
- 2002-09-06 US US10/487,094 patent/US20050065320A1/en not_active Abandoned
- 2002-09-06 EP EP02777408A patent/EP1423418B1/de not_active Expired - Lifetime
- 2002-09-06 ES ES02777408T patent/ES2268105T3/es not_active Expired - Lifetime
- 2002-09-06 AT AT02777408T patent/ATE327249T1/de not_active IP Right Cessation
- 2002-09-06 WO PCT/FR2002/003039 patent/WO2003020755A1/fr not_active Ceased
- 2002-09-06 JP JP2003525025A patent/JP2005508624A/ja active Pending

Also Published As

Publication number	Publication date
FR2829150B1 (fr)	2004-09-03
EP1423418B1 (de)	2006-05-24
JP2005508624A (ja)	2005-04-07
DE60211717D1 (de)	2006-06-29
US20050065320A1 (en)	2005-03-24
FR2829150A1 (fr)	2003-03-07
DE60211717T2 (de)	2007-05-03
WO2003020755A1 (fr)	2003-03-13
ES2268105T3 (es)	2007-03-16
EP1423418A1 (de)	2004-06-02

Similar Documents

Publication	Publication Date	Title
Bhat et al.	1993	The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275
EP1362127B1 (de)	2007-11-07	Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
ES2247591T3 (es)	2006-03-01	Proteasa-3 y 4 de apoptosis similares a la enzima conversora de interleuquina-1 beta.
CY1108520T1 (el)	2014-04-09	Ανασυνδιασμενοι ιοι γριππης για εμβολια και γονιδιακη θεραπεια
ATE486614T1 (de)	2010-11-15	Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
DE69934885D1 (de)	2007-03-08	Neue methoden und interferon defiziente substrate zur vermehrung von viren
DE60224508D1 (de)	2008-02-21	Wti-modifiziertes peptid
ATE405295T1 (de)	2008-09-15	Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine
ES2236688T3 (es)	2005-07-16	Variantes transdominantes tat del virus de la inmunodeficiencia humana.
WO2007110231A2 (en)	2007-10-04	MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
DE60235761D1 (de)	2010-05-06	Isoform des vegfs
ATE417618T1 (de)	2009-01-15	Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
ATE334231T1 (de)	2006-08-15	Neue polynukleotide und polypeptide des ifn alpha-17-gens
ATE327249T1 (de)	2006-06-15	Mutiertes env-gen, mutiertes env-glykoprotein und verwendungen
CY2605B2 (en)	2010-04-28	Nucleotide sequence coding for a flavin-containingmonooxygenase, corresponding protein and their ap plications in the fields of diagnosis and therapy
US5985601A (en)	1999-11-16	DNA encoding human cystatin E
IT1312569B1 (it)	2002-04-22	Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
TR200201081A2 (tr)	2002-11-21	Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları
ATE417064T1 (de)	2008-12-15	Hab18g/cd147, dessen antagonist und anwendung
EP0879240A1 (de)	1998-11-25	Menschlicher criptin wachstumsfaktor
AU717477B2 (en)	2000-03-30	Human cystatin E
AU762694B2 (en)	2003-07-03	Human criptin growth factor
US20110008889A1 (en)	2011-01-13	Serpin drugs for treatment of hiv infection and method of use thereof
WO2003038095A3 (fr)	2003-12-24	Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques
Powell et al.	1998	The aspartic proteinase from equine infectious anaemia virus

Legal Events

Date	Code	Title	Description
2006-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties